The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $36.00

Celldex Therapeutics (NASDAQ:CLDX) had its target price reduced by The Goldman Sachs Group from $42.00 to $36.00 in a report released on Monday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock.

CLDX has been the subject of several other research reports. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.38.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $21.10 on Monday. Celldex Therapeutics has a one year low of $18.61 and a one year high of $50.73. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -8.21 and a beta of 1.76. The business’s 50 day moving average price is $23.56 and its 200 day moving average price is $28.64.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. On average, analysts predict that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors have recently modified their holdings of the company. Polar Asset Management Partners Inc. grew its stake in shares of Celldex Therapeutics by 1,318.0% in the fourth quarter. Polar Asset Management Partners Inc. now owns 137,550 shares of the biopharmaceutical company’s stock valued at $3,476,000 after buying an additional 127,850 shares in the last quarter. TFG Asset Management GP Ltd acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $4,852,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Celldex Therapeutics by 13.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,317 shares of the biopharmaceutical company’s stock valued at $2,939,000 after buying an additional 13,722 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $7,707,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $835,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.